Erasca/$ERAS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Erasca
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
Ticker
$ERAS
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
103
ISIN
US29479A1088
Website
Erasca Metrics
BasicAdvanced
$397M
-
-$0.59
1.13
-
Price and volume
Market cap
$397M
Beta
1.13
52-week high
$3.45
52-week low
$1.01
Average daily volume
1.6M
Financial strength
Current ratio
12.352
Quick ratio
12.056
Long term debt to equity
11.519
Total debt to equity
12.719
Profitability
EBITDA (TTM)
-145.537
Management effectiveness
Return on assets (TTM)
-22.16%
Return on equity (TTM)
-45.82%
Valuation
Price to book
0.99
Price to tangible book (TTM)
0.99
Price to free cash flow (TTM)
-2.867
Free cash flow yield (TTM)
-34.88%
Free cash flow per share (TTM)
-48.84%
Growth
Earnings per share change (TTM)
-29.89%
3-year earnings per share growth (CAGR)
-27.63%
What the Analysts think about Erasca
Analyst ratings (Buy, Hold, Sell) for Erasca stock.
Bulls say / Bears say
Erasca's lead product, naporafenib, is advancing into a pivotal Phase 3 trial for patients with NRAS-mutant melanoma, indicating potential for significant clinical impact and future revenue growth. (marketscreener.com)
Major institutional investors, including Vanguard Group Inc., have increased their holdings in Erasca, reflecting confidence in the company's prospects. (marketbeat.com)
Analysts have issued positive ratings for Erasca, with Bank of America upgrading the stock to 'Buy' and setting a price target of $5.00, suggesting potential upside. (fintel.io)
Erasca was recently dropped from the S&P Biotechnology Select Industry Index, which could reduce its visibility among certain investors. (marketscreener.com)
Some institutional investors, such as Thrivent Financial for Lutherans, have reduced their positions in Erasca, potentially indicating concerns about the company's short-term performance. (defenseworld.net)
The company's stock price has experienced significant volatility, with a 52-week range between $1.64 and $3.45, which may deter risk-averse investors. (marketbeat.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.
Erasca Financial Performance
Revenues and expenses
Erasca Earnings Performance
Company profitability
Erasca News
AllArticlesVideos
Erasca to Present at Upcoming Investor Conferences in June
GlobeNewsWire·3 weeks ago
Erasca Reports First Quarter 2025 Business Updates and Financial Results
GlobeNewsWire·1 month ago
Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Erasca stock?
Erasca (ERAS) has a market cap of $397M as of June 20, 2025.
What is the P/E ratio for Erasca stock?
The price to earnings (P/E) ratio for Erasca (ERAS) stock is 0 as of June 20, 2025.
Does Erasca stock pay dividends?
No, Erasca (ERAS) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Erasca dividend payment date?
Erasca (ERAS) stock does not pay dividends to its shareholders.
What is the beta indicator for Erasca?
Erasca (ERAS) has a beta rating of 1.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.